0001819790-22-000030 | 10-Q | XBRL Viewer | Tarsus Pharmaceuticals INC

Print Document View Excel Document

Summary of Significant Accounting Policies and Use of Estimates	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Use of Estimates	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES (i) Basis of Presentation The Company’s Condensed Financial Statements have been prepared in conformity with generally accepted accounting principles ("GAAP") in the United States ("U.S.") for interim financial information and pursuant to Form 10-Q and with the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements. The interim Condensed Balance Sheet as of June 30, 2022, the interim Condensed Statements of Operations and Comprehensive (Loss) Income, and Stockholders’ Equity for the three and six months ended June 30, 2022 and 2021, and the interim Condensed Cash Flows for the six months ended June 30, 2022 and 2021 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. The financial data and other information disclosed in these notes related to the three and six-month periods are also unaudited. The Condensed Balance Sheet as of December 31, 2021 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three and six months ended June 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022 or any other interim or annual period. The accompanying interim unaudited Condensed Financial Statements should be read in conjunction with the audited financial statements and the related notes thereto in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 14, 2022. The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions involve judgments with respect to numerous factors that are difficult to forecast and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. There have been no significant changes in the Company’s significant accounting policies during the three and six months ended June 30, 2022, as compared with those disclosed in its Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 14, 2022. The accounting policies and estimates that most significantly impact the presented amounts within the accompanying Condensed Financial Statements are further described below. (ii) Cash and Cash Equivalents Cash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date. (iii) Marketable Securities and Long-Term Investments As of December 31, 2021, "marketable securities" represents LianBio common stock (see Note 7). These shares are reported within "long-term investments" on the Condensed Balance Sheet as of June 30, 2022, reflecting the intent to hold these shares for at least one year from the balance sheet date. These securities are designated as "available-for-sale" with associated gains or losses reported in "other expense, net" within the Condensed Statements of Operations and Comprehensive (Loss) Income for each reported period. (iv) Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits. In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (“COVID-19”) outbreak. The COVID-19 pandemic continues to evolve and its impact on the Company’s business will depend on several factors that are highly uncertain and unpredictable, including the efficacy and adoption of vaccines, future resurgences of the virus and its variants, and the speed at which government restrictions are lifted. To date, the Company’s operations have not been significantly impacted by the COVID-19 pandemic, though the Company continues to monitor the potential impact COVID-19 may have on its ongoing and planned clinical trials. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak may have on these activities or its financial condition. The Company’s results of operations involve numerous risks and uncertainties. Factors that could adversely impact the Company’s operating results and business objectives include, but are not limited to, (1) uncertainty of results of clinical trials, (2) uncertainty of regulatory approval of the Company’s potential product candidates, (3) uncertainty of market acceptance of its product candidates, (4) competition from substitute products and other companies, (5) securing and protecting proprietary technology and strategic relationships, and (6) dependence on key individuals and sole source suppliers. The Company’s product candidates require approvals from the U.S. Food and Drug Administration (“FDA”) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed, or the Company is unable to maintain approval for any product candidate, it could have a materially adverse impact on its business. (v) Revenue Recognition for Out-License Arrangements Overview The Company currently has one out-license arrangement that allows the third-party licensee to market the TP-03 product candidate (representing "functional intellectual property") in certain territories for a certain field of use and for a stated term - see Note 9. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract’s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of revenue recognition in each period. The Company's out-license arrangement, as described in Note 9, was analyzed under GAAP to determine whether the promised goods or services (which include the license, and know-how, data, and information necessary or reasonably useful for the research, development, manufacture, or commercialization of any licensed product, and governance committee services) are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is considered to not be distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition. The Company's out-license arrangement includes the following forms of consideration: (i) non-refundable upfront license payments, (ii) equity-based consideration, (iii) sales-based royalties, (iv) sales threshold milestones, (v) development milestone payments, and (vi) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, also adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the respective agreement. Contractual Terms for Receipt of Payments The contractual terms that establish the Company’s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: (1) Upfront License Fees: The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the out-license. The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements. (2) Development Milestones: The Company utilizes the “most likely amount” method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be "constrained" until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. (3) Regulatory Milestones: The Company utilizes the “most likely amount” method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise "constrained." Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement. (4) Royalties: Under the "sales-or-usage-based royalty exception" the Company recognizes revenue based on the contractual percentage of the licensee’s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from its out-licensing arrangements. (5) Sales Threshold Milestones: Similar to royalties, applying the "sales-or-usage-based royalty exception", the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from out-licensing arrangements. The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. A "performance obligation" is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract’s "transaction price" is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied. (vi) Research and Development Costs Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. These expenses also include internal costs directly attributable to in-development programs, including cost of certain salaries, payroll taxes, employee benefits, and stock-based compensation expense, as well as laboratory and clinical supplies, pre-clinical and clinical trial related expenses, clinical manufacturing costs, and the cost of services provided by outside contractors. The Company recognizes expense for pre-clinical studies and clinical trial activities performed by these third parties. This is typically based upon estimates of the proportion of work completed over the term of the individual study or trial, as well as patient enrollment and dosing events in accordance with agreements established with clinical research organizations (CROs) and clinical trial or pre-clinical study sites. The Company has entered, and may continue to enter into, license agreements to access and utilize intellectual property for drug development. In each case, the Company evaluates if the assets acquired in a transaction represent the acquisition of an asset or a business, as defined under applicable GAAP. The Company’s executed in-license agreements (see Note 8(b)) were evaluated and determined to represent asset acquisitions. Because these assets have not yet received regulatory approval and have no alternative future use, the purchase price for each was immediately recognized as research and development expense. In addition, any future milestone payments (whether in the form of cash or stock) made before product regulatory approval (that do not meet the definition of a derivative) will also be immediately recognized as research and development expense when paid or becomes payable, provided there is no alternative future use of the rights in other research and development projects. (vii) Stock-Based Compensation The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. The Black-Scholes pricing model is used to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing share price preceding the date of grant. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award’s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management’s judgment, including (a) the fair value of the Company’s common stock on the date of the option grant for all awards granted prior to its October 2020 Initial Public Offering ("IPO"), (b) the expected term of the stock option until its exercise by the recipient, (c) stock price volatility over the expected term, (d) the prevailing risk-free interest rate over the expected term, and (e) expected dividend payments over the expected term. Management estimates the expected term of awarded stock options utilizing the “simplified method” for awards as the Company does not yet have sufficient exercise history since its November 2016 corporate formation. Additionally, the Company lacks company-specific historical and implied volatility information of its stock since its IPO. Accordingly, management estimated this expected volatility based on a designated peer-group of publicly-traded companies for a look-back period, as of the date of grant, that corresponded with the expected term of the awarded stock option. The Company estimates the risk-free interest rate based upon the U.S. Department of the Treasury yield curve in effect at award grant for time periods that correspond with the expected term of the awarded stock option. The Company’s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future. The fair value of the Company’s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of grant. All stock-based compensation expense is reported in the Statements of Operations and Comprehensive (Loss) Income within "research and development" expense or "general and administrative" expense, based upon the assigned department of the award recipient. (viii) Net (Loss) Income per Share Basic net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net (loss) income per share is computed by dividing the net (loss) income by the weighted-average number of common stock equivalents outstanding for the period determined using the "treasury-stock method" and "if-converted method" as applicable. The Company’s "participating securities" include unvested common stock awards issued upon early exercise of certain stock options, as early exercised unvested common stock awards have a non-forfeitable right to dividends. The Company’s participating securities do not have a contractual obligation to share in the Company’s losses, so in periods of net losses, the "two-class method" of calculating basic and diluted earnings per share is not required. In periods of net income, basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Also, net income is attributed to both common stockholders and participating security holders, and therefore, net income is allocated to shares of common stock and participating securities, as if all of the earnings for the period had been distributed. Diluted earnings per share under the two-class method is calculated using the more dilutive of the treasury stock or the two-class method. Due to a net loss for the three and six months ended June 30, 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in this period. (ix) Fair Value Measurements Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: •Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date. •Level 2: Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public. •Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings are carried at fair value based on unobservable market inputs (see Note 7). Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented. (x) Comprehensive (Loss) Income Comprehensive (loss) income represents all changes in stockholders’ equity, except those resulting from distributions to stockholders. For all periods presented in the accompanying Condensed Financial Statements, comprehensive (loss) income was the same as reported net (loss) income. (xi) Recently Issued or Effective Accounting Standards Recently issued or effective accounting pronouncements that impact, or may have an impact, on the Company’s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company’s management to have no impact, or an immaterial impact, on its current and expected future financial position, results of operations, or cash flows.

Credit Facility Agreement

6 Months Ended

Jun. 30, 2022

Debt Disclosure [Abstract]

Credit Facility Agreement

CREDIT FACILITY AGREEMENT

On February 2, 2022, the Company executed the Credit Facility with Hercules and SVB that expires on February 2, 2027. The Credit Facility provides an aggregate principal amount of up to $175.0 million with tranched availability as follows: $40.0 million at its execution (to-date, $20.0 million drawn February 2022), $25.0 million upon submission of a New Drug Application ("NDA") with the FDA for TP-03, $35.0 million upon FDA approval of TP-03, $50.0 million upon achievement of product net revenue thresholds, and $25.0 million upon lender approval.

Each of these tranches may be drawn down in $5.0 million increments at the Company's election. The Credit Facility requires interest-only payments through February 1, 2026, followed by 12 months of principal amortization, unless extended for one year to its maturity, upon meeting certain contractual conditions. All unpaid amounts under the Credit Facility become due on its February 2, 2027 expiry.

Principal draws accrue interest on the outstanding principal balance at a floating interest rate per annum equal to the greater of either (i) The Wall Street Journal ("WSJ") prime rate plus 5.20% or (ii) 8.45%. At the execution date of the Credit Facility, the WSJ prime rate was 3.25% and further increased during 2022 to 4.75% as of June 30, 2022.

The Company is required to pay a fee upon the earlier of (i) February 2, 2027 or (ii) the date the Company prepays, in full or in part, the outstanding principal balance of the Credit Facility ("End of Term Charge"). The current End of Term Charge of $1.0 million was derived at the execution of the Credit Facility by multiplying 4.75% by the $20.0 million drawn at closing and is accreted to "interest expense" through maturity.

As of June 30, 2022, the carrying value of the Credit Facility (reported as "term loan, net" on the accompanying Condensed Balance Sheets) consisted of $20.0 million principal outstanding less legal and administrative issuance costs of approximately $0.9 million that were recorded as a contra-liability to the "term loan, net" and accreted to "interest expense" using the effective interest method during its term.

The calculated effective interest rate (i.e., coupon rate and other applicable fees) during the term of the credit facility was 10.90% for the six months ended June 30, 2022. As of December 31, 2021 the Company had no outstanding debt.

During the three and six months ended June 30, 2022, the Company recognized "interest expense" on its Condensed Statement of Operations and Comprehensive (Loss) Income in connection with the Credit Facility as follows:


	Three Months Ended June 30, 2022		Six Months Ended June 30, 2022
Interest expense for term loan	$	462	$	736
Accretion of end of term charge	48		79
Amortization of debt issuance costs	35		59
Total interest expense related to term loan	$	545	$	874

The principal balance of this term loan and related accretion and amortization as of June 30, 2022, were as follows:


	June 30, 2022
Term loan, gross (amount drawn)	$	20,000
Debt issuance costs (legal and other administrative fees)	(875)
Accretion of end of term charge	79
Accumulated amortization of debt issuance costs	58
Term loan, net	$	19,262

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Out-License Agreement (Details) - LianBio - License agreement - USD ($) $ in Millions		3 Months Ended		15 Months Ended
	Mar. 26, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received	$ 25.0		$ 25.0	$ 70.0
Clinical development milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment achieved	$ 45.0
Development and Regulatory Milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum milestone payments		$ 30.0		30.0
Drug Supply Agreement Milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum milestone payments		5.0		5.0
Sales-Based Milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum milestone payments		100.0		$ 100.0
Primary Endpoint Of Saturn-2 Trial
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment achieved		$ 15.0

Commitment & Contingencies (Tables)

6 Months Ended

Jun. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Lease asset and liability accounts

The below table summarizes the lease asset and liability accounts presented on the accompanying Condensed Balance Sheets:


Operating Leases	Condensed Balance Sheet Caption	June 30, 2022		December 31, 2021
Operating lease right-of-use assets— non-current	Operating lease right-of-use assets	$	813	$	1,074

Operating lease liability— current	Accounts payable and other accrued liabilities	$	605	$	609
Operating lease liability— non-current	Other long-term liabilities	300		585
Total lease liabilities		$	905	$	1,194

Components of lease cost

The components of total lease cost were as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Operating lease cost	$	142	$	60	$	285	$	120
Variable lease cost	62		11		101		71
Short-term lease cost	—		63		—		95
Total lease cost	$	204	$	134	$	386	$	286

Future contractual lease payments

The below table summarizes the (i) minimum lease payments over the next five years and thereafter, (ii) lease arrangement imputed interest, and (iii) present value of future lease payments:


Operating Leases - Future Payments	June 30, 2022
2022 (remaining six months)	$	164
2023	761
2024	66
2025	—
2026	—
Total future lease payments, undiscounted	$	991
(Less): Imputed interest	(86)
Present value of operating lease payments	$	905

Balance Sheet Account Detail - Other Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deposits	$ 71	$ 71
Equity warrant rights	264	663
Other long-term assets	265	392
Other assets	$ 600	$ 1,126

Commitment and Contingencies - Summary of Minimum Lease Payments (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
2022 (remaining six months)	$ 164
2023	761
2024	66
2025	0
2026	0
Total future lease payments, undiscounted	991
(Less): Imputed interest	(86)
Present value of operating lease payments	$ 905	$ 1,194

Description of Business and Presentation of Financial Statements	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Presentation of Financial Statements	DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS (a) Description of Business Tarsus Pharmaceuticals, Inc. (“Tarsus” or the “Company”) is a biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. (b) Liquidity Overview The Company has no product sales and has accumulated losses and negative cash flows from operations since inception (other than consideration received from an out-licensing agreement, as discussed in Note 9), resulting in an accumulated deficit of $72.7 million as of June 30, 2022 and $46.7 million as of December 31, 2021. The Company’s cash and cash equivalents were $245.4 million and $171.3 million as of June 30, 2022 and December 31, 2021, respectively. The Company expects to continue to incur operating losses and negative cash flows. The Company has funded its inception-to-date operations primarily through equity capital raises, proceeds from its out-license agreement, and draw downs on its credit facility. The Company estimates its existing capital resources will be sufficient to meet projected operating expense requirements for at least 12 months from the filing date of the accompanying Condensed Financial Statements in this Form 10-Q; accordingly, these financial statements have been prepared on a "going-concern" basis. The Company’s operations currently consist of its corporate organization build-out, intellectual property licensing activities, and preclinical and clinical study progression. The Company faces the clinical, business, and liquidity risks that are typically associated with biopharma companies; it must significantly invest in and conduct research and development activities, achieve research and development outcomes that are inherently uncertain, recruit and retain skilled personnel (including executive management), and expand and defend its intellectual property rights. Management expects the Company to continue to incur losses in the foreseeable future as a result of research and development activities and other operating expenses. The Company may be required to raise additional capital to fund its future operations. However, no assurance can be given as to whether financing will be available on terms acceptable to the Company, if at all. If the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. The Company's Credit Facility imposes additional covenants that restrict operations, including limitations on its ability to incur liens or additional debt, pay dividends, repurchase common stock, make certain investments, or engage in certain merger or asset sale transactions. Any debt financing or additional equity raise may contain terms that are not favorable to the Company or its stockholders. The Company’s potential inability to raise capital when needed could have a negative impact on its financial condition and ability to pursue planned business strategies. If the Company is unable to raise additional funds as required, it may need to delay, reduce, or terminate some or all of its development programs and clinical trials. The Company may also be required to sell or license its rights to product candidates in certain territories or indications that it would otherwise prefer to develop and commercialize on its own. If the Company is required to enter into collaborations and other arrangements to address its liquidity needs, it may have to give up certain rights that limit its ability to develop and commercialize product candidates or may have other terms that are not favorable to the Company or its stockholders, which could materially and adversely affect its business and financial prospects. These factors may adversely impact the Company's ability to achieve its business objectives and would likely have an adverse effect on its future business prospects, or even its ability to remain a going concern. (c) Operating Segment To date, the Company has operated and managed its business and financial information on an aggregate basis based on its organizational structure, for the purposes of evaluating financial performance and the allocation of capital and personnel resources, consistent with the way operations and investments are centrally managed and evaluated. Accordingly, the Company’s management determined that it operates one reportable operating segment. This single segment is focused exclusively on developing pharmaceutical products for eventual commercialization. (d) Emerging Growth Company Status The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to not take this exemption. As a result, it will adopt new or revised accounting standards on the relevant effective dates on which adoption of such standards is required for other public companies that are not emerging growth companies.

Credit Facility Agreement (Tables)

6 Months Ended

Jun. 30, 2022

Debt Disclosure [Abstract]

Summary of Interest Expense


	Three Months Ended June 30, 2022		Six Months Ended June 30, 2022
Interest expense for term loan	$	462	$	736
Accretion of end of term charge	48		79
Amortization of debt issuance costs	35		59
Total interest expense related to term loan	$	545	$	874

Balances of Debt, Debt Issuance Costs, and Accumulated Accretion

The principal balance of this term loan and related accretion and amortization as of June 30, 2022, were as follows:


	June 30, 2022
Term loan, gross (amount drawn)	$	20,000
Debt issuance costs (legal and other administrative fees)	(875)
Accretion of end of term charge	79
Accumulated amortization of debt issuance costs	58
Term loan, net	$	19,262

Balance Sheet Account Detail - Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Trade accounts payable and other	$ 4,093	$ 2,856
Operating lease liability, current	605	609
Accrued clinical studies	4,068	4,407
Contract liability	0	697
Accrued interest, current	160	0
Income taxes payable	0	55
Employee stock option pre-vesting exercise liability	12	56
Accounts payable and other accrued liabilities	$ 8,938	$ 8,680

Stock-Based Compensation - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 3,532	$ 2,794	$ 6,206	$ 4,157
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	984	427	1,662	771
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 2,548	$ 2,367	$ 4,544	$ 3,386

Fair Value Measurements - Financial Instruments Measured at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Assets:
Common stock in LianBio (included in "long-term investments")	$ 169	$ 483
Equity warrants in LianBio (included in "other assets")	264	663
Total assets measured at fair value	245,796	172,478
Money market funds
Assets:
Money market funds	245,363	171,332
Level 1
Assets:
Common stock in LianBio (included in "long-term investments")	169	483
Equity warrants in LianBio (included in "other assets")	0	0
Total assets measured at fair value	245,532	171,815
Level 1 \| Money market funds
Assets:
Money market funds	245,363	171,332
Level 2
Assets:
Common stock in LianBio (included in "long-term investments")	0	0
Equity warrants in LianBio (included in "other assets")	0	0
Total assets measured at fair value	0	0
Level 2 \| Money market funds
Assets:
Money market funds	0	0
Level 3
Assets:
Common stock in LianBio (included in "long-term investments")	0	0
Equity warrants in LianBio (included in "other assets")	264	663
Total assets measured at fair value	264	663
Level 3 \| Money market funds
Assets:
Money market funds	$ 0	$ 0

Description of Business and Presentation of Financial Statements (Details) $ / shares in Units, $ in Thousands			3 Months Ended	6 Months Ended
	Jun. 01, 2022 USD ($) $ / shares shares	May 05, 2022 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) shares	Jun. 30, 2022 USD ($) segment	Feb. 02, 2022 USD ($)	Dec. 31, 2021 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit			$ 72,653	$ 72,653		$ 46,672
Cash and cash equivalents			245,363	$ 245,363		$ 171,332
Number of reportable segments \| segment				1
Number of operating segments \| segment				1
Follow-On Public Offering
Debt Instrument [Line Items]
Stock issued (up to)		$ 70,600	$ 74,300
Stock issued (shares) \| shares		5,600,000	5,889,832
Original issue price (usd per share) \| $ / shares		$ 13.50
Stock issued, gross proceeds		$ 75,600	$ 79,500
Underwriters' option
Debt Instrument [Line Items]
Stock issued (up to)	$ 3,700
Stock issued (shares) \| shares	289,832	840,000
Original issue price (usd per share) \| $ / shares	$ 13.50
Stock issued, gross proceeds	$ 3,900
Line of Credit
Debt Instrument [Line Items]
Credit facility, aggregate principal amount					$ 175,000
Increments to draw on credit facility at company's election					$ 5,000

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2022

Fair Value Disclosures [Abstract]

Financial instruments measured at fair value

The table below summarizes certain financial instruments measured at fair value that are included within the accompanying balance sheets, and their designation among the three fair value measurement categories (see Note 2(ix)):


	June 30, 2022 Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	245,363	$	—	$	—	$	245,363
Common stock in LianBio (included in "long-term investments")	169		—		—		169
Equity warrants in LianBio (included in "other assets")	—		—		264		264
Total assets measured at fair value	$	245,532	$	—	$	264	$	245,796

	December 31, 2021 Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	171,332	—		—		$	171,332
Common stock in LianBio (included in "marketable securities")	483		—		—		$	483
Equity warrants in LianBio (included in "other assets")	—		—		663		$	663
Total assets measured at fair value	$	171,815	$	—	$	663	$	172,478

Changes in fair value of equity warrants

resented in these accompanying financial statements as follows:


	Value of equity warrants (see Note 3(b))
Fair value as of December 31, 2021	$	663

Revaluation of equity warrant value in "other expense, net" within the Condensed Statement of Operations	(245)
Fair value as of March 31, 2022	$	418
Recognition of equity warrant value in "total revenues" within the Condensed Statement of Operations for the three months ended June 30, 2022	103
Revaluation of equity warrant value in "other expense, net" within the Condensed Statement of Operations for the three months ended June 30, 2022	(257)
Fair value as of June 30, 2022	$	264


	Value of equity warrants (see Note 3(b))
Fair value as of December 31, 2020	$	—
Initial fair value estimate of equity warrant value in "total revenues"	1,233
Fair value as of March 31, 2021	$	1,233
Recognition of equity warrant value in "total revenues" within the Condensed Statement of Operations for the three months ended June 30, 2021	719
Revaluation of equity warrant value in "other expense, net" within the Condensed Statement of Operations for the three months ended June 30, 2021	(876)
Fair value as of June 30, 2021	$	1,076

Commitment & Contingencies - Lease Asset and Liability Accounts (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating lease right-of-use assets	$ 813	$ 1,074
Operating lease liability, current	$ 605	$ 609
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accounts payable and other accrued liabilities	Accounts payable and other accrued liabilities
Operating lease liability, non-current	$ 300	$ 585
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities	Other long-term liabilities
Present value of operating lease payments	$ 905	$ 1,194

Fair Value Measurements - Changes in Fair Value of Equity Warrants (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning of period	$ 418	$ 663	$ 1,233	$ 0
Revaluation of equity warrants				1,233
Fair value, end of period	264	418	1,076	$ 1,233
Other income (expense), net
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Revaluation of equity warrants	(257)	$ (245)	(876)
Total revenues
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Revaluation of equity warrants	$ 103		$ 719

Credit Facility Agreement - Summary of Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Debt Disclosure [Abstract]
Interest expense for term loan	$ 462	$ 736
Accretion of end of term charge	48	79
Amortization of debt issuance costs	35	59
Total interest expense related to term loan	$ 545	$ 874

Stockholders' Equity and Equity Incentive Plans - Shares Reserved for Issuance (Details) - shares	Jun. 30, 2022	Dec. 31, 2021
Equity [Abstract]
Stock options reserved for future grant (shares)	8,678,128	9,266,200
Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan	2,682,601	2,493,488
Stock options issued and outstanding (shares)	3,739,078	2,759,830
Restricted stock units outstanding under 2020 Equity Incentive Plan	440,737	17,251
Total shares of common stock reserved (shares)	15,540,544	14,536,769

Commitment & Contingencies - Employment Arrangements (Details)	Jun. 30, 2022 arrangement
Commitments and Contingencies Disclosure [Abstract]
Number of employment arrangements with executive officers	8

Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
Condensed Statements of Cash Flows - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Cash Flows From Operating Activities:
Net (loss) income	$ (25,981)	$ 16,721
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization	133	189
Amortization and accretion of term loan-related costs	137	0
Stock-based compensation	6,206	4,157
Non-cash lease expense	226	87
Loss on disposal of property and equipment	0	70
Loss on lease termination	0	2
Unrealized loss on equity investments	313	0
Change in fair value of equity warrants issued by licensee	502	876
Unrealized gain from transactions denominated in a foreign currency	(1)	(8)
Issuance of common stock upon in-license agreement milestone achievement	0	5,494
Changes in operating assets and liabilities:
Accounts receivable	(17)	(20,000)
Other receivables	(510)	(137)
Prepaid expenses and other current assets	(254)	(1,527)
Other non-current assets	(75)	(2,326)
Accounts payable and other accrued liabilities	(135)	4,622
Accrued payroll and benefits	(18)	430
Other long-term liabilities	(71)	107
Net cash used in operating activities	(19,545)	8,757
Cash Flows From Investing Activities:
Purchases of property and equipment	(283)	(191)
Cash used in investing activities	(283)	(191)
Cash Flows From Financing Activities:
Proceeds from issuance of common stock upon follow-on public offering, net of paid issuance costs	74,570	0
Proceeds from sale of common stock under employee stock purchase plan	222	0
Proceeds from exercise of vested stock options	17	20
Payment of deferred offering costs	(75)	0
Proceeds from term loan	20,000	0
Payment of term loan issuance costs	(875)	0
Net cash provided by financing activities	93,859	20
Net increase in cash and cash equivalents	74,031	8,586
Cash and cash equivalents — beginning of period	171,332	168,149
Cash and cash equivalents — end of period	245,363	176,735
Supplemental Disclosures Noncash Investing and Financing Activities:
"Interest expense" paid in cash	127	0
Additions of "property and equipment, net" included within "accounts payable and other accrued liabilities"	59	0
Expensing of "operating lease right-of-use assets" upon lease termination	0	(38)
Stock issued for in-license agreements included within "research and development" expense	0	5,494
Deferred offering costs included within "additional-paid in capital"	184	0
Deferred offering costs included within "accounts payable and accrued liabilities"	$ 0	$ 281

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2022

Share-Based Payment Arrangement [Abstract]

Stock-based compensation

tock-based compensation expense for the three and six months ended June 30, 2022 and 2021 was reported as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Research and development	$	984	$	427	$	1,662	$	771
General and administrative	2,548		2,367		4,544		3,386
Total stock-based compensation	$	3,532	$	2,794	$	6,206	$	4,157

Balance Sheet Account Detail (Tables)

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Property and equipment, net of accumulated depreciation

“Property and equipment, net” consists of the following:


	June 30, 2022		December 31, 2021
Furniture and fixtures	$	596	$	596
Office equipment	197		84
Laboratory equipment	167		167
Leasehold improvements	357		129
Property and equipment, at cost	1,317		976
(Less): Accumulated depreciation and amortization	354		221
Property and equipment, net	$	963	$	755

Other assets

"Other assets" consists of the following:


	June 30, 2022		December 31, 2021
Deposits	$	71	$	71
Equity warrants issued by licensee (Note 7)	264		663
Other long-term assets	265		392
Other assets	$	600	$	1,126

Accounts payable and accrued liabilities

“Accounts payable and other accrued liabilities” consists of the following:


	June 30, 2022		December 31, 2021
Trade accounts payable and other	$	4,093	$	2,856

Operating lease liability, current	605		609
Accrued clinical studies	4,068		4,407
Contract liability	—		697
Accrued interest, current	160		—
Income taxes payable	—		55
Employee stock option pre-vesting exercise liability	12		56
Accounts payable and other accrued liabilities	$	8,938	$	8,680

Other long-term liabilities

“Other long-term liabilities” consists of the following:


	June 30, 2022		December 31, 2021
Operating lease liability, non-current	$	300	$	585
Lotilaner licensor liability	43		114

Other long-term liabilities	$	343	$	699

Condensed Statements of Preferred Stock and Stockholders' Equity (Parenthetical) $ in Thousands	3 Months Ended
	Jun. 30, 2022 USD ($)
Statement of Stockholders' Equity [Abstract]
Stock issued, issuance costs	$ 5,246

Stock-Based Compensation

6 Months Ended

Jun. 30, 2022

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

STOCK-BASED COMPENSATION

Stock-Based Compensation Summary

Stock-based compensation expense is recorded to "research and development" or "general and administrative" expenses in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income, based on the functional role of each recipient. Stock-based compensation expense for the three and six months ended June 30, 2022 and 2021 was reported as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Research and development	$	984	$	427	$	1,662	$	771
General and administrative	2,548		2,367		4,544		3,386
Total stock-based compensation	$	3,532	$	2,794	$	6,206	$	4,157

Balance Sheet Account Detail

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Balance Sheet Account Detail

BALANCE SHEET ACCOUNT DETAIL

The composition of selected captions within the accompanying Condensed Balance Sheets are summarized below:

(a) Property and Equipment, Net

“Property and equipment, net” consists of the following:


	June 30, 2022		December 31, 2021
Furniture and fixtures	$	596	$	596
Office equipment	197		84
Laboratory equipment	167		167
Leasehold improvements	357		129
Property and equipment, at cost	1,317		976
(Less): Accumulated depreciation and amortization	354		221
Property and equipment, net	$	963	$	755

Depreciation expense (included within “total operating expenses” in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income) for the three months ended June 30, 2022 and 2021 was $92 thousand and $125 thousand, respectively, and for the six months ended June 30, 2022 and 2021 was $133 thousand and $189 thousand, respectively.

(b) Other Assets

"Other assets" consists of the following:


	June 30, 2022		December 31, 2021
Deposits	$	71	$	71
Equity warrants issued by licensee (Note 7)	264		663
Other long-term assets	265		392
Other assets	$	600	$	1,126

“Accounts payable and other accrued liabilities” consists of the following:


	June 30, 2022		December 31, 2021
Trade accounts payable and other	$	4,093	$	2,856

Operating lease liability, current	605		609
Accrued clinical studies	4,068		4,407
Contract liability	—		697
Accrued interest, current	160		—
Income taxes payable	—		55
Employee stock option pre-vesting exercise liability	12		56
Accounts payable and other accrued liabilities	$	8,938	$	8,680

(d) Other Long-Term Liabilities

“Other long-term liabilities” consists of the following:


	June 30, 2022		December 31, 2021
Operating lease liability, non-current	$	300	$	585
Lotilaner licensor liability	43		114

Other long-term liabilities	$	343	$	699

Summary of Significant Accounting Policies and Use of Estimates (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Operating Segment	To date, the Company has operated and managed its business and financial information on an aggregate basis based on its organizational structure, for the purposes of evaluating financial performance and the allocation of capital and personnel resources, consistent with the way operations and investments are centrally managed and evaluated. Accordingly, the Company’s management determined that it operates one reportable operating segment. This single segment is focused exclusively on developing pharmaceutical products for eventual commercialization.
Basis of Presentation	Basis of Presentation The Company’s Condensed Financial Statements have been prepared in conformity with generally accepted accounting principles ("GAAP") in the United States ("U.S.") for interim financial information and pursuant to Form 10-Q and with the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, the accompanying Condensed Financial Statements do not include all of the information and footnotes required by GAAP for complete financial statements. The interim Condensed Balance Sheet as of June 30, 2022, the interim Condensed Statements of Operations and Comprehensive (Loss) Income, and Stockholders’ Equity for the three and six months ended June 30, 2022 and 2021, and the interim Condensed Cash Flows for the six months ended June 30, 2022 and 2021 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, which consist of only normal and recurring adjustments for the fair presentation of its financial information. The financial data and other information disclosed in these notes related to the three and six-month periods are also unaudited. The Condensed Balance Sheet as of December 31, 2021 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for annual financial statements. The condensed interim operating results for three and six months ended June 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022 or any other interim or annual period. The accompanying interim unaudited Condensed Financial Statements should be read in conjunction with the audited financial statements and the related notes thereto in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 14, 2022. The preparation of financial statements in conformity with GAAP and with the rules and regulations of the SEC requires management to make informed estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. These estimates and assumptions involve judgments with respect to numerous factors that are difficult to forecast and may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. There have been no significant changes in the Company’s significant accounting policies during the three and six months ended June 30, 2022, as compared with those disclosed in its Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 14, 2022. The accounting policies and estimates that most significantly impact the presented amounts within the accompanying Condensed Financial Statements are further described below.
Cash and Cash Equivalents	Cash and Cash EquivalentsCash and cash equivalents consist of bank deposits and highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty, with original maturities of three months or less from the purchase date.
Marketable Securities and Long-Term Investments	Marketable Securities and Long-Term InvestmentsAs of December 31, 2021, "marketable securities" represents LianBio common stock (see Note 7). These shares
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents in deposits at financial institutions that exceed federally insured limits. In March 2020, the World Health Organization declared a pandemic related to the global novel coronavirus disease 2019 (“COVID-19”) outbreak. The COVID-19 pandemic continues to evolve and its impact on the Company’s business will depend on several factors that are highly uncertain and unpredictable, including the efficacy and adoption of vaccines, future resurgences of the virus and its variants, and the speed at which government restrictions are lifted. To date, the Company’s operations have not been significantly impacted by the COVID-19 pandemic, though the Company continues to monitor the potential impact COVID-19 may have on its ongoing and planned clinical trials. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak may have on these activities or its financial condition. The Company’s results of operations involve numerous risks and uncertainties. Factors that could adversely impact the Company’s operating results and business objectives include, but are not limited to, (1) uncertainty of results of clinical trials, (2) uncertainty of regulatory approval of the Company’s potential product candidates, (3) uncertainty of market acceptance of its product candidates, (4) competition from substitute products and other companies, (5) securing and protecting proprietary technology and strategic relationships, and (6) dependence on key individuals and sole source suppliers. The Company’s product candidates require approvals from the U.S. Food and Drug Administration (“FDA”) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed, or the Company is unable to maintain approval for any product candidate, it could have a materially adverse impact on its business.
Revenue	Revenue Recognition for Out-License Arrangements Overview The Company currently has one out-license arrangement that allows the third-party licensee to market the TP-03 product candidate (representing "functional intellectual property") in certain territories for a certain field of use and for a stated term - see Note 9. The accounting and reporting of revenue for out-license arrangements requires significant judgment for: (a) identification of the number of performance obligations within the contract, (b) the contract’s transaction price for allocation (including variable consideration), (c) the stand-alone selling price for each identified performance obligation, and (d) the timing and amount of revenue recognition in each period. The Company's out-license arrangement, as described in Note 9, was analyzed under GAAP to determine whether the promised goods or services (which include the license, and know-how, data, and information necessary or reasonably useful for the research, development, manufacture, or commercialization of any licensed product, and governance committee services) are distinct or must be accounted for as part of a combined performance obligation. In making these assessments, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own, and/or whether the required expertise is readily available. If the license is considered to not be distinct, the license is combined with other promised goods or services as a combined performance obligation for revenue recognition. The Company's out-license arrangement includes the following forms of consideration: (i) non-refundable upfront license payments, (ii) equity-based consideration, (iii) sales-based royalties, (iv) sales threshold milestones, (v) development milestone payments, and (vi) regulatory milestone payments. Revenue is recognized in proportion to the allocated transaction price when (or as) the respective performance obligation is satisfied. The Company evaluates the progress related to each milestone at each reporting period and, if necessary, also adjusts the probability of achievement and related revenue recognition. The measure of progress, and thereby periods over which revenue is recognized, is subject to estimates by management and may change over the course of the respective agreement. Contractual Terms for Receipt of Payments The contractual terms that establish the Company’s right to collect specified amounts from its customers and that require contemporaneous evaluation and documentation under GAAP for the corresponding timing and amount of revenue recognition, are as follows: (1) Upfront License Fees: The Company determines whether non-refundable license fee consideration is recognized at the time of contract execution (i.e., when the license is transferred to the customer and the customer is able to use and benefit from the license) or over the actual (or implied) contractual period of the out-license. The Company also evaluates whether it has any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer to determine whether any combined performance obligation is satisfied over time or at a point in time. Upfront payments may require deferral of revenue recognition to a future period until the Company performs obligations under these arrangements. (2) Development Milestones: The Company utilizes the “most likely amount” method to estimate the amount of consideration to which it will be entitled for achievement of development milestones as these represent variable consideration. For those payments based on development milestones (e.g., patient dosing in a clinical study or the achievement of statistically significant clinical results), the Company assesses the probability that the milestone will be achieved, including its ability to control the timing or likelihood of achievement, and any associated revenue constraint. Given the high degree of uncertainty around the occurrence of these events, the Company determines the milestone and other contingent amounts to be "constrained" until the uncertainty associated with these payments is resolved. At each reporting period, the Company re-evaluates this associated revenue recognition constraint. Any resulting adjustments are recorded to revenue on a cumulative catch-up basis, and reflected in the financial statements in the period of adjustment. (3) Regulatory Milestones: The Company utilizes the “most likely amount” method to estimate the consideration to which it will be entitled and recognizes revenue in the period regulatory approval occurs (the performance obligation is satisfied) as these represent variable consideration. Amounts constrained as variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company evaluates whether the milestones are considered probable of being reached and not otherwise "constrained." Accordingly, due to the inherent uncertainty of achieving regulatory approval, associated milestones are deemed constrained for revenue recognition until achievement. (4) Royalties: Under the "sales-or-usage-based royalty exception" the Company recognizes revenue based on the contractual percentage of the licensee’s sale of products to its customers at the later of (i) the occurrence of the related product sales or (ii) the date upon which the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue from its out-licensing arrangements. (5) Sales Threshold Milestones: Similar to royalties, applying the "sales-or-usage-based royalty exception", the Company recognizes revenue from sales threshold milestones at the later of (i) the period the licensee achieves the one-time annual product sales levels in their territories for which the Company is contractually entitled to a specified lump-sum receipt, or (ii) the date upon which the performance obligation to which some or all of the milestone has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any sales threshold milestone revenue from out-licensing arrangements. The Company re-evaluates the measure of progress to each performance obligation in each reporting period as uncertain events are resolved and other changes in circumstances occur. A "performance obligation" is a promise in a contract to transfer a distinct good or service and is the unit of accounting. A contract’s "transaction price" is allocated among each distinct performance obligation based on relative standalone selling price and recognized when, or as, the applicable performance obligation is satisfied.
Research and Development Costs	Research and Development Costs Research and development costs are expensed as incurred or as certain upfront or milestone payments become contractually due to licensors upon the achievement of clinical or regulatory events. These expenses also include internal costs directly attributable to in-development programs, including cost of certain salaries, payroll taxes, employee benefits, and stock-based compensation expense, as well as laboratory and clinical supplies, pre-clinical and clinical trial related expenses, clinical manufacturing costs, and the cost of services provided by outside contractors. The Company recognizes expense for pre-clinical studies and clinical trial activities performed by these third parties. This is typically based upon estimates of the proportion of work completed over the term of the individual study or trial, as well as patient enrollment and dosing events in accordance with agreements established with clinical research organizations (CROs) and clinical trial or pre-clinical study sites. The Company has entered, and may continue to enter into, license agreements to access and utilize intellectual property for drug development. In each case, the Company evaluates if the assets acquired in a transaction represent the acquisition of an asset or a business, as defined under applicable GAAP. The Company’s executed in-license agreements (see Note 8(b)) were evaluated and determined to represent asset acquisitions. Because these assets have not yet received regulatory approval and have no alternative future use, the purchase price for each was immediately recognized as research and development expense. In addition, any future milestone payments (whether in the form of cash or stock) made before product regulatory approval (that do not meet the definition of a derivative) will also be immediately recognized as research and development expense when paid or becomes payable, provided there is no alternative future use of the rights in other research and development projects.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes stock-based compensation expense for equity awards granted to employees, consultants, and members of its Board of Directors. The Black-Scholes pricing model is used to estimate the fair value of stock option awards as of the date of grant. The fair value of restricted stock units is representative of the closing share price preceding the date of grant. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award’s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related expense on an accelerated attribution method, if and when it concludes that it is highly probable that the performance condition will be achieved. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture. The measurement of the fair value of stock option awards and recognition of stock-based compensation expense requires assumptions to be estimated by management that involve inherent uncertainties and the application of management’s judgment, including (a) the fair value of the Company’s common stock on the date of the option grant for all awards granted prior to its October 2020 Initial Public Offering ("IPO"), (b) the expected term of the stock option until its exercise by the recipient, (c) stock price volatility over the expected term, (d) the prevailing risk-free interest rate over the expected term, and (e) expected dividend payments over the expected term. Management estimates the expected term of awarded stock options utilizing the “simplified method” for awards as the Company does not yet have sufficient exercise history since its November 2016 corporate formation. Additionally, the Company lacks company-specific historical and implied volatility information of its stock since its IPO. Accordingly, management estimated this expected volatility based on a designated peer-group of publicly-traded companies for a look-back period, as of the date of grant, that corresponded with the expected term of the awarded stock option. The Company estimates the risk-free interest rate based upon the U.S. Department of the Treasury yield curve in effect at award grant for time periods that correspond with the expected term of the awarded stock option. The Company’s expected dividend yield is zero because it has never paid cash dividends and does not expect to for the foreseeable future. The fair value of the Company’s common stock is based on the closing quoted market price of its common stock as reported by the Nasdaq Global Select Market on the date of grant. All stock-based compensation expense is reported in the Statements of Operations and Comprehensive (Loss) Income within "research and development" expense or "general and administrative" expense, based upon the assigned department of the award recipient.
Net (Loss) Income per Share	Net (Loss) Income per Share Basic net (loss) income per share is calculated by dividing the net (loss) income by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. Diluted net (loss) income per share is computed by dividing the net (loss) income by the weighted-average number of common stock equivalents outstanding for the period determined using the "treasury-stock method" and "if-converted method" as applicable. The Company’s "participating securities" include unvested common stock awards issued upon early exercise of certain stock options, as early exercised unvested common stock awards have a non-forfeitable right to dividends. The Company’s participating securities do not have a contractual obligation to share in the Company’s losses, so in periods of net losses, the "two-class method" of calculating basic and diluted earnings per share is not required. In periods of net income, basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Also, net income is attributed to both common stockholders and participating security holders, and therefore, net income is allocated to shares of common stock and participating securities, as if all of the earnings for the period had been distributed. Diluted earnings per share under the two-class method is calculated using the more dilutive of the treasury stock or the two-class method. Due to a net loss for the three and six months ended June 30, 2022, all otherwise potentially dilutive securities are antidilutive, and accordingly, the reported basic net loss per share equals the reported diluted net loss per share in this period.
Fair Value Measurements	Fair Value Measurements Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: •Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date. •Level 2: Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public. •Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to the short maturities for each. The Company's equity warrant holdings are carried at fair value based on unobservable market inputs (see Note 7). Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented.
Comprehensive (Loss) Income	Comprehensive (Loss) Income Comprehensive (loss) income represents all changes in stockholders’ equity, except those resulting from distributions to stockholders. For all periods presented in the accompanying Condensed Financial Statements, comprehensive (loss) income was the same as reported net (loss) income.
Recently Issued or Effective Accounting Standards	Recently Issued or Effective Accounting StandardsRecently issued or effective accounting pronouncements that impact, or may have an impact, on the Company’s financial statements have been discussed within the footnote to which each relates. Other recent accounting pronouncements not disclosed in these Condensed Financial Statements have been determined by the Company’s management to have no impact, or an immaterial impact, on its current and expected future financial position, results of operations, or cash flows.

Stockholders' Equity and Equity Incentive Plans - Additional Information (Details) $ / shares in Units, $ in Millions			3 Months Ended
	Jun. 01, 2022 USD ($) $ / shares shares	May 05, 2022 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) vote shares	Dec. 31, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, outstanding (shares)			26,644,252	20,698,737
Common stock votes \| vote			1
Common stock, issued (shares)			26,650,078	20,726,580
Total shares of common stock reserved (in shares)			15,540,544	14,536,769
Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan			2,682,601	2,493,488
Follow-On Public Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued (shares)		5,600,000	5,889,832
Original issue price (usd per share) \| $ / shares		$ 13.50
Stock issued, gross proceeds \| $		$ 75.6	$ 79.5
Stock issued, net proceeds \| $		$ 70.6	$ 74.3
Underwriters' option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued (shares)	289,832	840,000
Original issue price (usd per share) \| $ / shares	$ 13.50
Stock issued, gross proceeds \| $	$ 3.9
Stock issued, net proceeds \| $	$ 3.7

Credit Facility Agreement (Details) - USD ($)			6 Months Ended
Credit Facility Agreement (Details) - USD ($)	Jun. 30, 2022	Feb. 02, 2022	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Principal outstanding	$ 20,000,000		$ 20,000,000
Debt issuance costs	$ 875,000		875,000
Line of Credit
Debt Instrument [Line Items]
Credit facility, aggregate principal amount		$ 175,000,000
Increments to draw on credit facility at company's election		$ 5,000,000
Interest rate		8.45%
Interest rate	4.75%	3.25%
Principal outstanding	$ 20,000,000		20,000,000	$ 0
End of term charge			1,000,000
End of term charge, interest rate		4.75%
Debt issuance costs	$ 900,000		$ 900,000
Effective interest rate	10.90%		10.90%
Line of Credit \| Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate		5.20%
Line of Credit \| Credit Facility, Tranche One
Debt Instrument [Line Items]
Credit facility, aggregate principal amount		$ 40,000,000
Line of Credit \| Credit Facility, Tranche Two
Debt Instrument [Line Items]
Credit facility, aggregate principal amount		20,000,000
Line of Credit \| Credit Facility, Tranche Three
Debt Instrument [Line Items]
Credit facility, aggregate principal amount		25,000,000
Line of Credit \| Credit Facility, Tranche Four
Debt Instrument [Line Items]
Credit facility, aggregate principal amount		35,000,000
Line of Credit \| Credit Facility, Tranche Five
Debt Instrument [Line Items]
Credit facility, aggregate principal amount		50,000,000
Line of Credit \| Credit Facility, Tranche Six
Debt Instrument [Line Items]
Credit facility, aggregate principal amount		$ 25,000,000

Balance Sheet Account Detail - Other Long-Term Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating lease liability, non-current	$ 300	$ 585
Lotilaner licensor liability	43	114
Other long-term liabilities	$ 343	$ 699

Commitment & Contingencies - In-License Agreement for Lotilaner (Details) - USD ($)		1 Months Ended					3 Months Ended			6 Months Ended		15 Months Ended
	Mar. 26, 2021	Jun. 30, 2022	Apr. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jan. 31, 2019	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development							$ 9,603,000	$ 7,204,000		$ 21,684,000	$ 23,465,000
Common stock issued for license agreement, value									$ 5,494,000	0	$ 5,494,000
License agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development			$ 2,000,000			$ 1,000,000
Common stock issued for license agreement (shares)					222,460
Common stock issued for license agreement, value					$ 3,100,000
Common stock issued for license agreement, share price (usd per share)					$ 14.0003
Additional shares to be issued upon 18-month anniversary of contract execution (shares)				187,500
Additional shares to be issued upon 18-month anniversary of contract execution, value				$ 5,500,000
Additional shares to be issued upon 18-month anniversary of contract execution, share price (usd per share)				$ 29.30
License agreement \| LianBio
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received	$ 25,000,000							25,000,000				$ 70,000,000
License agreement \| Elanco
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development		$ 1,500,000
Upfront payment received								$ 2,500,000
License agreement \| Clinical milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development					$ 1,000,000
Maximum milestone payments		4,500,000				3,000,000	4,500,000			4,500,000		4,500,000
License agreement \| Commercial and sales milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum milestone payments		$ 77,000,000				$ 79,000,000	$ 77,000,000			$ 77,000,000		$ 77,000,000

Condensed Statements of Operations and Comprehensive (Loss) Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues:
Total revenues	$ 15,277	$ 22,017	$ 15,816	$ 55,449
Operating expenses:
Research and development	9,603	7,204	21,684	23,465
General and administrative	10,376	6,794	18,322	11,954
Total operating expenses	20,501	14,735	40,561	37,453
(Loss) income from operations before other (expense) income and income taxes	(5,224)	7,282	(24,745)	17,996
Other (expense) income:
Interest (expense) income, net	(247)	7	(563)	16
Other income (expense), net	106	(39)	143	(73)
Unrealized loss on equity investments	(121)	0	(313)	0
Change in fair value of equity warrants issued by licensee	(257)	(876)	(502)	(876)
Total other expense, net	(519)	(908)	(1,235)	(933)
Provision for income taxes	0	(29)	(1)	(342)
Net (loss) income	(5,743)	6,345	(25,981)	16,721
Comprehensive (loss) income	$ (5,743)	$ 6,345	$ (25,981)	$ 16,721
Earnings Per Share [Abstract]
Net (loss) per share, basic (usd per share)	$ (0.24)	$ 0.31	$ (1.15)	$ 0.81
Net (loss) income per share, diluted (usd per share)	$ (0.24)	$ 0.29	$ (1.15)	$ 0.76
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Weighted-average shares outstanding, basic (shares)	24,332,531	20,555,258	22,531,384	20,446,246
Weighted-average shares outstanding, diluted (shares)	24,332,531	21,966,599	22,531,384	21,895,304
License fees and Collaboration
Operating expenses:
Cost of license fees and collaboration revenue	$ 522	$ 737	$ 555	$ 2,034
License fees
Revenues:
Total revenues	13,893	19,048	13,893	52,359
Collaboration revenue
Revenues:
Total revenues	$ 1,384	$ 2,969	$ 1,923	$ 3,090

Balance Sheet Account Detail - Property and Equipment, Net of Accumulated Depreciation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$ 1,317		$ 1,317		$ 976
(Less): Accumulated depreciation and amortization	354		354		221
Property and equipment, net	963		963		755
Depreciation	92	$ 125	133	$ 189
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	596		596		596
Office equipment
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	197		197		84
Laboratory equipment
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	167		167		167
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$ 357		$ 357		$ 129

Summary of Significant Accounting Policies and Use of Estimates (Details)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Expected dividend yield	0.00%

Net (Loss) Income Per Share (Tables)

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Net (loss) income per share, basis and diluted

The following table sets forth the computation of basic and diluted net (loss) income per share:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Basic EPS
Net (loss) income	$	(5,743)	$	6,345	$	(25,981)	$	16,721
Less: undistributed income allocated to participating securities	—		46		—		133
Net (loss) income available to common shareholders	$	(5,743)	$	6,299	$	(25,981)	$	16,588

Basic weighted average shares outstanding	24,332,531		20,555,258		22,531,384		20,446,246
Net (loss) income per share—basic	$	(0.24)	$	0.31	$	(1.15)	$	0.81

Diluted EPS
Net (loss) income	$	(5,743)	$	6,345	$	(25,981)	$	16,721
Less: undistributed income reallocated to participating securities	—		43		—		124
Net (loss) income available to common shareholders	$	(5,743)	$	6,302	$	(25,981)	$	16,597

Basic weighted average shares outstanding	24,332,531		20,555,258		22,531,384		20,446,246
Effect of dilutive securities:
Common stock options	—		1,411,341		—		1,449,058
Diluted weighted average shares outstanding	24,332,531		21,966,599		22,531,384		21,895,304
Net (loss) income per share—diluted	$	(0.24)	$	0.29	$	(1.15)	$	0.76

Outstanding potentially dilutive securities

The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per

share because their impact under the “treasury stock method” and “if-converted method” would have been anti-dilutive for the

periods presented:


	Three Months Ended June 30,		Six Months Ended June 30, 2022
	2022	2021	2022	2021
Stock options, unexercised—vested and unvested	3,739,078	803,238	3,739,078	803,238
Stock options exercised prior to vesting— remaining unvested	5,826	130,153	5,826	130,153
Restricted stock units—unvested	440,737	4,257	440,737	4,257
Total	4,185,641	937,648	4,185,641	937,648

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (usd per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (shares)	10,000,000	10,000,000
Preferred stock, issued (shares)	0	0
Preferred stock, outstanding (shares)	0	0
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock, authorized (shares)	200,000,000	200,000,000
Common stock, issued (shares)	26,650,078	20,726,580
Common stock, outstanding (shares)	26,644,252	20,698,737
Common stock, subject to repurchase (shares)	5,826	27,840

Commitment & Contingencies - Facility Leases (Details) $ in Thousands	Jun. 30, 2022 USD ($) contract	Dec. 31, 2021 USD ($) contract
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets \| $	$ 813	$ 1,074
Weighted average remaining lease term	1 year 7 months
Estimated incremental borrowing rate	10.00%
Irvine office and laboratory facility
Lessee, Lease, Description [Line Items]
Number of leases \| contract	4	4

Out-License Agreement	6 Months Ended
Out-License Agreement	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Out-License Agreement	OUT-LICENSE AGREEMENT Out-License of TP-03 Commercial Rights in Greater China in March 2021 On March 26, 2021, the Company entered into an out-license agreement with LianBio for its exclusive development and commercialization rights of TP-03 (lotilaner ophthalmic solution, 0.25%) in the People’s Republic of China, Hong Kong, Macau, and Taiwan (the “China Territory”) for the treatment of Demodex blepharitis and Meibomian Gland Disease (the “China Out-License”). LianBio is contractually responsible for all clinical development and commercialization activities and costs within the China Territory. Through June 30, 2022, the Company received payments from LianBio totaling $70.0 million that is comprised of initial consideration of $25.0 million and $45.0 million for the achievement of three clinical development milestones, including $15.0 million received in June 2022. The Company is eligible to receive further consideration from LianBio upon the achievement of additional milestones, including: (i) TP-03 clinical development and regulatory milestones of up to $30.0 million, (ii) expected drug supply agreement milestone of $5.0 million, (iii) TP-03 sales-based milestones for the China Territory of up to $100 million, (iv) tiered mid-to-high-teen royalties for China Territory TP-03 product sales, and (v) LianBio equity, subject to regulatory milestone achievement for vesting. For the three and six months ended June 30, 2022 and 2021, the Company reported "license fees" and "collaboration revenue" in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income, in accordance with the revenue recognition accounting policy described in Note 2(vii). Reported revenue in each presented period relates to the satisfaction performance obligations relating to (i) the transfer of TP-03 license rights in the China Territory to LianBio and (ii) the completion of clinical activities and providing LianBio with the related data for its pivotal trials of TP-03 in the treatment of Demodex blepharitis.

Net (Loss) Income Per Share

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Net (Loss) Income Per Share

NET (LOSS) INCOME PER SHARE

The following table sets forth the computation of basic and diluted net (loss) income per share:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Basic EPS
Net (loss) income	$	(5,743)	$	6,345	$	(25,981)	$	16,721
Less: undistributed income allocated to participating securities	—		46		—		133
Net (loss) income available to common shareholders	$	(5,743)	$	6,299	$	(25,981)	$	16,588

Basic weighted average shares outstanding	24,332,531		20,555,258		22,531,384		20,446,246
Net (loss) income per share—basic	$	(0.24)	$	0.31	$	(1.15)	$	0.81

Diluted EPS
Net (loss) income	$	(5,743)	$	6,345	$	(25,981)	$	16,721
Less: undistributed income reallocated to participating securities	—		43		—		124
Net (loss) income available to common shareholders	$	(5,743)	$	6,302	$	(25,981)	$	16,597

Basic weighted average shares outstanding	24,332,531		20,555,258		22,531,384		20,446,246
Effect of dilutive securities:
Common stock options	—		1,411,341		—		1,449,058
Diluted weighted average shares outstanding	24,332,531		21,966,599		22,531,384		21,895,304
Net (loss) income per share—diluted	$	(0.24)	$	0.29	$	(1.15)	$	0.76

The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per

share because their impact under the “treasury stock method” and “if-converted method” would have been anti-dilutive for the

periods presented:


	Three Months Ended June 30,		Six Months Ended June 30, 2022
	2022	2021	2022	2021
Stock options, unexercised—vested and unvested	3,739,078	803,238	3,739,078	803,238
Stock options exercised prior to vesting— remaining unvested	5,826	130,153	5,826	130,153
Restricted stock units—unvested	440,737	4,257	440,737	4,257
Total	4,185,641	937,648	4,185,641	937,648

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2022	Aug. 05, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-39614
Entity Registrant Name	TARSUS PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-4717861
Entity Address, Address Line One	15440 Laguna Canyon Road, Suite 160
Entity Address, City or Town	Irvine
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92618
City Area Code	(949)
Local Phone Number	409-9820
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	TARS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Smaller Reporting Company	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		26,658,468
Amendment Flag	false
Entity Central Index Key	0001819790
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2

Credit Facility Agreement - Balances of Debt, Debt Issuance Costs, and Accumulated Accretion (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Debt Disclosure [Abstract]
Term loan, gross (amount drawn)	$ 20,000
Debt issuance costs (legal and other administrative fees)	(875)
Accretion of end of term charge	79
Accumulated amortization of debt issuance costs	58
Term loan, net	$ 19,262

- Definition

Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Commitment & Contingencies - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 142	$ 60	$ 285	$ 120
Variable lease cost	62	11	101	71
Short-term lease cost	0	63	0	95
Total lease cost	$ 204	$ 134	$ 386	$ 286

Net (Loss) Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Basic EPS
Net (loss) income	$ (5,743)	$ (20,238)	$ 6,345	$ 10,376	$ (25,981)	$ 16,721
Less: undistributed income allocated to participating securities	0		46		0	133
Net (loss) income available to common shareholders	$ (5,743)		$ 6,299		$ (25,981)	$ 16,588
Basic weighted average shares outstanding (shares)	24,332,531		20,555,258		22,531,384	20,446,246
Net (loss) per share, basic (usd per share)	$ (0.24)		$ 0.31		$ (1.15)	$ 0.81
Diluted EPS
Net (loss) income	$ (5,743)	$ (20,238)	$ 6,345	$ 10,376	$ (25,981)	$ 16,721
Less: undistributed income reallocated to participating securities	0		43		0	124
Net (loss) income available to common shareholders	$ (5,743)		$ 6,302		$ (25,981)	$ 16,597
Basic weighted average shares outstanding (shares)	24,332,531		20,555,258		22,531,384	20,446,246
Effect of dilutive securities:
Common stock options (shares)	0		1,411,341		0	1,449,058
Diluted weighted average shares outstanding (shares)	24,332,531		21,966,599		22,531,384	21,895,304
Net (loss) income per share, diluted (usd per share)	$ (0.24)		$ 0.29		$ (1.15)	$ 0.76

Condensed Statements of Preferred Stock and Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Beginning balance (shares) at Dec. 31, 2020	0
Beginning balance at Dec. 31, 2020	$ 0
Ending balance (shares) at Mar. 31, 2021	0
Ending balance at Mar. 31, 2021	$ 0
Beginning balance (shares) at Dec. 31, 2020		20,323,201
Beginning balance at Dec. 31, 2020	165,980	$ 4	$ 198,821	$ (32,845)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	10,376			10,376
Recognition of stock-based compensation expense	1,363		1,363
Exercise of vested stock options (shares)		13,773
Exercise of vested stock options	19		19
Shares issued as consideration for in-license rights (shares)		187,500
Shares issued as consideration for in-license rights	5,494		5,494
Ending balance (shares) at Mar. 31, 2021		20,524,474
Ending balance at Mar. 31, 2021	$ 183,232	$ 4	205,697	(22,469)
Beginning balance (shares) at Dec. 31, 2020	0
Beginning balance at Dec. 31, 2020	$ 0
Ending balance (shares) at Jun. 30, 2021	0
Ending balance at Jun. 30, 2021	$ 0
Beginning balance (shares) at Dec. 31, 2020		20,323,201
Beginning balance at Dec. 31, 2020	165,980	$ 4	198,821	(32,845)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	16,721
Shares issued as consideration for in-license rights	5,494
Ending balance (shares) at Jun. 30, 2021		20,573,951
Ending balance at Jun. 30, 2021	$ 192,471	$ 4	208,591	(16,124)
Beginning balance (shares) at Mar. 31, 2021	0
Beginning balance at Mar. 31, 2021	$ 0
Ending balance (shares) at Jun. 30, 2021	0
Ending balance at Jun. 30, 2021	$ 0
Beginning balance (shares) at Mar. 31, 2021		20,524,474
Beginning balance at Mar. 31, 2021	183,232	$ 4	205,697	(22,469)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	6,345			6,345
Recognition of stock-based compensation expense	2,794		2,794
Exercise of vested stock options (shares)		255
Exercise of vested stock options	1		1
Lapse of repurchase obligation for stock option exercises, prior to vesting (shares)		49,222
Lapse of repurchase obligation for stock option exercises, prior to vesting	99		99
Ending balance (shares) at Jun. 30, 2021		20,573,951
Ending balance at Jun. 30, 2021	$ 192,471	$ 4	208,591	(16,124)
Beginning balance (shares) at Dec. 31, 2021	0
Beginning balance at Dec. 31, 2021	$ 0
Ending balance (shares) at Mar. 31, 2022	0
Ending balance at Mar. 31, 2022	$ 0
Beginning balance (shares) at Dec. 31, 2021	20,698,737	20,698,737
Beginning balance at Dec. 31, 2021	$ 166,730	$ 4	213,398	(46,672)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(20,238)			(20,238)
Recognition of stock-based compensation expense	2,674		2,674
Exercise of vested stock options (shares)		225
Issuance of common stock upon the vesting of restricted stock units (shares)		4,257
Lapse of repurchase obligation for stock option exercises, prior to vesting (shares)		15,309
Lapse of repurchase obligation for stock option exercises, prior to vesting	31		31
Ending balance (shares) at Mar. 31, 2022		20,718,528
Ending balance at Mar. 31, 2022	$ 149,197	$ 4	216,103	(66,910)
Beginning balance (shares) at Dec. 31, 2021	0
Beginning balance at Dec. 31, 2021	$ 0
Ending balance (shares) at Jun. 30, 2022	0
Ending balance at Jun. 30, 2022	$ 0
Beginning balance (shares) at Dec. 31, 2021	20,698,737	20,698,737
Beginning balance at Dec. 31, 2021	$ 166,730	$ 4	213,398	(46,672)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(25,981)
Shares issued as consideration for in-license rights	$ 0
Ending balance (shares) at Jun. 30, 2022	26,644,252	26,644,252
Ending balance at Jun. 30, 2022	$ 221,505	$ 5	294,153	(72,653)
Beginning balance (shares) at Mar. 31, 2022	0
Beginning balance at Mar. 31, 2022	$ 0
Ending balance (shares) at Jun. 30, 2022	0
Ending balance at Jun. 30, 2022	$ 0
Beginning balance (shares) at Mar. 31, 2022		20,718,528
Beginning balance at Mar. 31, 2022	149,197	$ 4	216,103	(66,910)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(5,743)			(5,743)
Recognition of stock-based compensation expense	3,532		3,532
Exercise of vested stock options (shares)		7,056
Exercise of vested stock options	17		17
Issuance of common stock upon the vesting of restricted stock units (shares)		4,257
Lapse of repurchase obligation for stock option exercises, prior to vesting (shares)		6,705
Lapse of repurchase obligation for stock option exercises, prior to vesting	13		13
Issuance of common stock upon follow-up public offering, net of issuance costs (shares)		5,889,832
Issuance of common stock upon follow-on public offering, net of issuance costs of $5,246	74,267	$ 1	74,266
Shares issued in connection with the employee stock purchase plan (shares)		17,874
Shares issued in connection with the employee stock purchase plan	$ 222		222
Ending balance (shares) at Jun. 30, 2022	26,644,252	26,644,252
Ending balance at Jun. 30, 2022	$ 221,505	$ 5	$ 294,153	$ (72,653)

Stockholders' Equity and Equity Incentive Plans

6 Months Ended

Jun. 30, 2022

Equity [Abstract]

Stockholders' Equity and Equity Incentive Plans

STOCKHOLDERS’ EQUITY AND EQUITY INCENTIVE PLANS

Common Stock Outstanding and Reserves for Future Issuance

As of June 30, 2022, the Company had 26.7 million and 26.6 million common shares issued and outstanding, respectively. As of December 31, 2021, the Company had 20.7 million common shares issued and outstanding, respectively. Each share of common stock is entitled to one vote.

The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan is summarized below:


	June 30, 2022	December 31, 2021
Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans	8,678,128	9,266,200
Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan	2,682,601	2,493,488
Stock options issued and outstanding under 2020 and 2016 Equity Incentive Plans	3,739,078	2,759,830
Restricted stock units outstanding under 2020 Equity Incentive Plan	440,737	17,251
Total shares of common stock reserved	15,540,544	14,536,769

Follow-On Public Offering

On May 5, 2022, the Company completed a follow-on public offering under its Shelf Registration Statement for an initial underwritten sale of 5,600,000 shares of its common stock at a price of $13.50 per share. This resulted in gross proceeds of $75.6 million, before underwriting discounts, commissions and other estimated offering expenses, for net proceeds of $70.6 million.

The Company also granted the underwriters a 30-day option to purchase up to 840,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. On June 1, 2022, the underwriters partially exercised this option by purchasing an additional 289,832 shares of the Company's common stock at the public offering price of $13.50 per share for additional gross proceeds of $3.9 million, before underwriting discounts and commissions for net proceeds of $3.7 million.

After giving effect to the exercise of the underwriters’ option, the Company sold 5,889,832 shares for total gross proceeds of $79.5 million, before underwriting discounts, commissions and other estimated offering expenses. Total net proceeds during the second quarter of 2022 from this offering were $74.3 million.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Fair Value Measurements

6 Months Ended

Jun. 30, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements

FAIR VALUE MEASUREMENTS


	June 30, 2022 Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	245,363	$	—	$	—	$	245,363
Common stock in LianBio (included in "long-term investments")	169		—		—		169
Equity warrants in LianBio (included in "other assets")	—		—		264		264
Total assets measured at fair value	$	245,532	$	—	$	264	$	245,796

	December 31, 2021 Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	171,332	—		—		$	171,332
Common stock in LianBio (included in "marketable securities")	483		—		—		$	483
Equity warrants in LianBio (included in "other assets")	—		—		663		$	663
Total assets measured at fair value	$	171,815	$	—	$	663	$	172,478

Money Market Funds

Money market fund holdings are included in "cash and cash equivalents" on the accompanying Condensed Balance Sheets and are classified within Level 1 of the fair value hierarchy because they have readily-available market prices in active markets that are publicly observable at the measurement date. These money market funds are invested in U.S. Treasury bills and notes and other securities issued or guaranteed as to principal and interest by the U.S. Government or its agencies.

Equity Warrants

In March 2021, contemporaneous with the China Out-License transaction (see Note 9), the Company and LianBio, executed a warrant agreement for the Company to purchase, in three tranches, a stated number of common shares in LianBio, a pharmaceutical company focused on the Greater China and other Asian markets (NASDAQ: LIAN). These warrants vest or have vested upon the achievement of certain clinical and regulatory events and have an exercise price at common stock par value.

In June 2021, one of these three warrant tranches vested and converted to 78,373 shares of LianBio common stock, reported within "marketable securities" as of December 31, 2021, and within "long-term investments" as of June 30, 2022. LianBio common stock is classified within Level 1 of the fair value hierarchy, given its publicly reported price on the NASDAQ Global Market.

In May 2022, the second warrant tranche vested, but has not yet been exercised, leaving one remaining unvested tranche. The second and third warrant tranche remain classified as Level 3 in the fair value measurement hierarchy as of June 30, 2022 and December 31, 2021 and is presented within "other assets" in the accompanying Condensed Balance Sheets (see Note 3(b)). The most significant assumptions used in the option pricing valuation model as of each balance sheet date to determine its fair value included: LianBio common stock volatility (based on the historical volatility of similar companies), the probability of regulatory milestone achievement for vesting, and the application of an assumed discount rate.

The estimated fair value of these equity warrants will be remeasured each reporting period with adjustments reported within "other expense, net" on the accompanying Statements of Operations and Comprehensive (Loss) Income, until exercised or expired, and is presented in these accompanying financial statements as follows:


	Value of equity warrants (see Note 3(b))
Fair value as of December 31, 2021	$	663

Revaluation of equity warrant value in "other expense, net" within the Condensed Statement of Operations	(245)
Fair value as of March 31, 2022	$	418
Recognition of equity warrant value in "total revenues" within the Condensed Statement of Operations for the three months ended June 30, 2022	103
Revaluation of equity warrant value in "other expense, net" within the Condensed Statement of Operations for the three months ended June 30, 2022	(257)
Fair value as of June 30, 2022	$	264


	Value of equity warrants (see Note 3(b))
Fair value as of December 31, 2020	$	—
Initial fair value estimate of equity warrant value in "total revenues"	1,233
Fair value as of March 31, 2021	$	1,233
Recognition of equity warrant value in "total revenues" within the Condensed Statement of Operations for the three months ended June 30, 2021	719
Revaluation of equity warrant value in "other expense, net" within the Condensed Statement of Operations for the three months ended June 30, 2021	(876)
Fair value as of June 30, 2021	$	1,076

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitment & Contingencies

6 Months Ended

Jun. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitment & Contingencies

COMMITMENTS & CONTINGENCIES

(a) Facility Leases

Overview

In the ordinary course of business, the Company enters lease agreements with unaffiliated third parties for facilities and office equipment. As of June 30, 2022 and December 31, 2021, the Company had four active leases in Irvine, California for adjacent office and laboratory suites that each expire on January 31, 2024.

The Company's operating leases have annual rent that is payable monthly and carry fixed annual increases. Under these arrangements the Company is responsible for real estate taxes, certain operating expenses, and common area maintenance. Since these costs are variable in nature, they are expensed as incurred and excluded from the reported amounts on the accompanying Condensed Balance Sheets, summarized below. During the year ended December 31, 2021, and the six months ended June 30, 2022, the Company had no sublease arrangements with it as lessor.

Financial Reporting Captions

The below table summarizes the lease asset and liability accounts presented on the accompanying Condensed Balance Sheets:


Operating Leases	Condensed Balance Sheet Caption	June 30, 2022		December 31, 2021
Operating lease right-of-use assets— non-current	Operating lease right-of-use assets	$	813	$	1,074

Operating lease liability— current	Accounts payable and other accrued liabilities	$	605	$	609
Operating lease liability— non-current	Other long-term liabilities	300		585
Total lease liabilities		$	905	$	1,194

Components of Lease Expense

The liability associated with each lease is amortized over the respective lease term using the “effective interest rate method.” The Company’s "operating lease right-of-use assets" are amortized over each lease term on a straight-line basis to lease expense and is allocated to "research and development" and "general and administrative" expenses in the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income. The Company combines lease and non-lease components in the recognition of lease expense. The components of total lease cost were as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Operating lease cost	$	142	$	60	$	285	$	120
Variable lease cost	62		11		101		71
Short-term lease cost	—		63		—		95
Total lease cost	$	204	$	134	$	386	$	286

Weighted-Average Remaining Lease Term and Applied Discount Rate

As of June 30, 2022, the Company's facility leases had a weighted average remaining lease term of 1 year, 7 months. The weighted-average estimated incremental borrowing rate of 10% was utilized to present value future minimum lease payments since an implicit interest rate in each at-market lease agreement was not determinable.

Future Contractual Lease Payments

The below table summarizes the (i) minimum lease payments over the next five years and thereafter, (ii) lease arrangement imputed interest, and (iii) present value of future lease payments:


Operating Leases - Future Payments	June 30, 2022
2022 (remaining six months)	$	164
2023	761
2024	66
2025	—
2026	—
Total future lease payments, undiscounted	$	991
(Less): Imputed interest	(86)
Present value of operating lease payments	$	905

(b) In-License Agreements for Lotilaner

January 2019 Agreement for Skin and Eye Disease or Conditions in Humans

In January 2019, the Company entered into a license agreement with Elanco Tiergesundheit AG (“Elanco”) for exclusive worldwide rights to certain intellectual property for the development and commercialization of lotilaner in the treatment or cure of any eye or skin disease or condition in humans, as amended in June 2022 (the "Eye and Derm Elanco Agreement"). The Company has sole financial responsibility for related development, regulatory, and commercialization activities.

The Company made a $1.0 million upfront payment at execution of the Eye and Derm Elanco Agreement in January 2019, and also made a required $1.0 million clinical milestone payment in September 2020, associated with the first two U.S. pivotal trials for the treatment of Demodex blepharitis. The Company paid an additional $2.0 million for its second pivotal trial milestone in April 2021, which was recorded in “research and development” expense in the accompanying Statements of Operations and Comprehensive Loss for the three months ended June 30, 2021. As part of the China Out-License discussed in Note 9, the Company made a contractual payment in the amount of $2.5 million to Elanco following the receipt of $25 million of initial proceeds from LianBio during the second quarter of 2021. In June 2022, the Company made a contractual prepayment of $1.5 million that can be applied towards any milestones that become due under the Eye and Derm Elanco Agreement and/or the All Human Uses Elanco Agreement. This prepayment is included within "prepaid expenses and other current assets" on the accompanying Condensed Balance Sheet as of June 30, 2022.

The Company may make further cash payments to Elanco under the Eye and Derm Elanco Agreement upon achievement of certain clinical milestones in the treatment of human skin diseases using lotilaner for an aggregate maximum of $3.0 million and various commercial and sales threshold milestones for an aggregate maximum of $79.0 million. In addition, the Company will be obligated to pay tiered contractual royalties to Elanco in the mid to high single digits of its net sales. If the Company receives certain types of payments from its sublicensees, it will be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, except for territories in which it achieved applicable regulatory approval prior to sublicense execution.

September 2020 Agreement for All Other Diseases or Conditions in Humans

In September 2020, the Company executed an expanded in-license agreement with Elanco, granting it a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention, or cure of "all other" diseases and conditions in humans (i.e., beyond that of the eye or skin), as amended in June 2022 (the “All Human Uses Elanco Agreement”). In September 2020, the Company issued Elanco 222,460 shares of its common stock at the execution of the All Human Uses Elanco Agreement with an estimated fair value of $3.1 million ($14.0003 per share, approximating the issuance price of the Company's Series C preferred stock in September 2020).

The Company is required to make cash payments to Elanco under the All Human Uses Elanco Agreement upon the achievement of various clinical milestones for an aggregate maximum of $4.5 million and various commercial and sales threshold milestones for an aggregate maximum of $77.0 million. In addition, the Company will be obligated to pay contractual royalties to Elanco in the single digits of its net product sales. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay Elanco a variable percentage in the low to mid double-digits of such proceeds, except for territories in which it achieved applicable regulatory approval prior to sublicense execution.

In March 2021, the Company entered into the China Out-License agreement with LianBio (see Note 9) that required it to grant Elanco an additional fixed 187,500 shares of its common stock that otherwise would have been issuable no later than the 18-month anniversary of the All Human Uses Elanco Agreement for its continued license exclusivity. These issued shares were valued at $5.5 million, based on the Company's stock closing price of $29.30 per share on the date this issuance became contractually required and is reported within "research and development" expense within the accompanying Condensed Statements of Operations and Comprehensive (Loss) Income for the six months ended June 30, 2021.

The Company has entered into employment agreements with eight of its executive officers. These agreements provide for the payment of certain benefits upon separation of employment under specified circumstances, such as termination without cause, or termination in connection with a change in control event.

(d) Litigation Contingencies

From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is currently not aware of any such matters where there is at least a reasonable probability that a material loss, if any, has been or will be incurred for financial statement recognition.

(e) Indemnities and Guarantees

The Company has certain indemnity commitments, under which it may be required to make payments to its officers and directors in relation to certain transactions to the maximum extent permitted under applicable laws. The duration of these indemnities vary, and in certain cases, are indefinite and do not provide for any limitation of maximum payments. The Company has not been obligated to make any such payments to date and no liabilities have been recorded for this contingency in the accompanying Condensed Balance Sheets.

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 245,363	$ 171,332
Marketable securities	0	483
Accounts receivable	17	0
Other receivables	603	92
Prepaid expenses and other current assets	4,300	4,045
Total current assets	250,283	175,952
Property and equipment, net	963	755
Operating lease right-of-use assets	813	1,074
Long-term investments	169	0
Other assets	600	1,126
Total assets	252,828	178,907
Current liabilities:
Accounts payable and other accrued liabilities	8,938	8,680
Accrued payroll and benefits	2,780	2,798
Total current liabilities	11,718	11,478
Term loan, net	19,262	0
Other long-term liabilities	343	699
Total liabilities	31,323	12,177
Commitments and contingencies (Note 8)
Stockholders’ equity:
#REF!	0	0
Common stock, $0.0001 par value; 200,000,000 shares authorized; 26,650,078 shares issued and 26,644,252 outstanding, which excludes 5,826 shares subject to repurchase at June 30, 2022 (unaudited); 20,726,580 shares issued and 20,698,737 outstanding, which excludes 27,840 shares subject to repurchase at December 31, 2021	5	4
Additional paid-in capital	294,153	213,398
Accumulated deficit	(72,653)	(46,672)
Total stockholders’ equity	221,505	166,730
Total liabilities and stockholders’ equity	$ 252,828	$ 178,907

Fair Value Measurements - Additional Information (Details)	1 Months Ended
	Mar. 31, 2021 tranche	Jun. 30, 2021 warrant shares
Fair Value Disclosures [Abstract]
Number of tranches \| tranche	3
Number of vested warrants		1
Number of warrants		3
Equity securities (in shares) \| shares		78,373

Stockholders' Equity and Equity Incentive Plans (Tables)

6 Months Ended

Jun. 30, 2022

Equity [Abstract]

Stock details

The Company's outstanding equity awards and shares reserved for future issuance under its 2020 and 2016 Equity Incentive Plans and 2020 Employee Stock Purchase Plan is summarized below:


	June 30, 2022	December 31, 2021
Common stock awards reserved for future issuance under 2020 and 2016 Equity Incentive Plans	8,678,128	9,266,200
Common stock awards reserved for future issuance under the 2020 Employee Stock Purchase Plan	2,682,601	2,493,488
Stock options issued and outstanding under 2020 and 2016 Equity Incentive Plans	3,739,078	2,759,830
Restricted stock units outstanding under 2020 Equity Incentive Plan	440,737	17,251
Total shares of common stock reserved	15,540,544	14,536,769

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

+ Details

Net (Loss) Income Per Share - Antidilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net income (loss) per share	4,185,641	937,648	4,185,641,000	937,648,000
Stock options, unexercised—vested and unvested
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net income (loss) per share	3,739,078	803,238	3,739,078,000	803,238,000
Stock options exercised prior to vesting— remaining unvested
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net income (loss) per share	5,826	130,153	5,826,000	130,153,000
Restricted stock units—unvested
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net income (loss) per share	440,737	4,257	440,737,000	4,257,000